An ActRIIA fusion protein got FDA approved for PAH treatment

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure.

Related Keywords

Maria Osipova , , Implications Across Disease , Protein , Flood , Blood Pressure , Heart , Heart Failure , Lungs , Pulmonary Arterial Hypertension , Eceptor , Research ,